美国退伍军人中BNT162b2与mRNA-1273疫苗的比较有效性
该研究采用目标试验模拟方法,利用美国退伍军人电子健康记录,纳入2021年1月4日至5月14日(alpha变异株流行期)首次接种BNT162b2或mRNA-1273的退伍军人,按危险因素1:1匹配,每组219,842人。随访24周,BNT162b2组相对mRNA-1273组每1000人超额事件数:确诊感染1.23(95%CI 0.72-1.81)、症状性Covid-19 0.44(95%CI 0.25-0.70)、Covid-19住院0.55(95%CI 0.36-0.83)、Covid-19 ICU入住0.10(95%CI 0.00-0.26)、Covid-19死亡0.02(95%CI -0.06-0.12)。在delta变异株流行期(2021年7月1日至9月20日接种)的第二个目标试验中,12周随访确诊感染超额风险为6.54/1000人(95%CI -2.58-11.82)。结论认为两种mRNA疫苗接种后24周Covid-19结局风险均低,但mRNA-1273风险更低,且在alpha和delta变异株流行期模式一致。
要点
- alpha变异株流行期24周随访,BNT162b2组确诊感染风险5.75/1000人(95%CI 5.39-6.23),mRNA-1273组4.52/1000人(95%CI 4.17-4.84)。
- BNT162b2相对mRNA-1273每1000人超额事件:确诊感染1.23(95%CI 0.72-1.81)、症状性Covid-19 0.44(95%CI 0.25-0.70)。
- BNT162b2相对mRNA-1273每1000人超额事件:Covid-19住院0.55(95%CI 0.36-0.83)、ICU入住0.10(95%CI 0.00-0.26)、死亡0.02(95%CI -0.06-0.12,未达统计学显著)。
- delta变异株流行期12周随访,BNT162b2相对mRNA-1273确诊感染超额风险6.54/1000人(95%CI -2.58-11.82)。
- 两种mRNA疫苗接种后24周Covid-19结局风险均低,但mRNA-1273风险低于BNT162b2,alpha和delta变异株流行期模式一致。
适用人群与场景
- 美国退伍军人中于2021年1月4日至5月14日(alpha变异株流行期)首次接种BNT162b2或mRNA-1273者,按危险因素1:1匹配后每组219,842人。
- 第二个目标试验纳入2021年7月1日至9月20日(delta变异株流行期)接种的退伍军人。
研究设计与关键结果
- 研究设计:利用美国退伍军人电子健康记录模拟目标试验,比较BNT162b2与mRNA-1273疫苗有效性,按危险因素1:1匹配,每组219,842人。
- alpha变异株流行期24周随访,BNT162b2组确诊感染风险5.75/1000人(95%CI 5.39-6.23),mRNA-1273组4.52/1000人(95%CI 4.17-4.84)。
- BNT162b2相对mRNA-1273每1000人超额事件:确诊感染1.23(95%CI 0.72-1.81)、症状性Covid-19 0.44(95%CI 0.25-0.70)、Covid-19住院0.55(95%CI 0.36-0.83)、Covid-19 ICU入住0.10(95%CI 0.00-0.26)、Covid-19死亡0.02(95%CI -0.06-0.12)。
- delta变异株流行期12周随访,BNT162b2相对mRNA-1273确诊感染超额风险6.54/1000人(95%CI -2.58-11.82)。
- 结论:两种mRNA疫苗接种后24周Covid-19结局风险均低,但mRNA-1273风险低于BNT162b2,alpha和delta变异株流行期模式一致。
证据类型、等级与局限
- 证据类型:基于电子健康记录的目标试验模拟(观察性研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The messenger RNA (mRNA)-based vaccines BNT162b2 and mRNA-1273 are more than 90% effective against coronavirus disease 2019 (Covid-19). However, their comparative effectiveness for a range of outcomes across diverse populations is unknown.
METHODS: We emulated a target trial using the electronic health records of U.S. veterans who received a first dose of the BNT162b2 or mRNA-1273 vaccine between January 4 and May 14, 2021, during a period marked by predominance of the SARS-CoV-2 B.1.1.7 (alpha) variant. We matched recipients of each vaccine in a 1:1 ratio according to their risk factors. Outcomes included documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, symptomatic Covid-19, hospitalization for Covid-19, admission to an intensive care unit (ICU) for Covid-19, and death from Covid-19. We estimated risks using the Kaplan-Meier estimator. To assess the influence of the B.1.617.2 (delta) variant, we emulated a second target trial that involved veterans vaccinated between July 1 and September 20, 2021.
RESULTS: Each vaccine group included 219,842 persons. Over 24 weeks of follow-up in a period marked by alpha-variant predominance, the estimated risk of documented infection was 5.75 events per 1000 persons (95% confidence interval [CI], 5.39 to 6.23) in the BNT162b2 group and 4.52 events per 1000 persons (95% CI, 4.17 to 4.84) in the mRNA-1273 group. The excess number of events per 1000 persons for BNT162b2 as compared with mRNA-1273 was 1.23 (95% CI, 0.72 to 1.81) for documented infection, 0.44 (95% CI, 0.25 to 0.70) for symptomatic Covid-19, 0.55 (95% CI, 0.36 to 0.83) for hospitalization for Covid-19, 0.10 (95% CI, 0.00 to 0.26) for ICU admission for Covid-19, and 0.02 (95% CI, -0.06 to 0.12) for death from Covid-19. The corresponding excess risk (BNT162b2 vs. mRNA-1273) of documented infection over 12 weeks of follow-up in a period marked by delta-variant predominance was 6.54 events per 1000 persons (95% CI, -2.58 to 11.82).
CONCLUSIONS: The 24-week risk of Covid-19 outcomes was low after vaccination with mRNA-1273 or BNT162b2, although risks were lower with mRNA-1273 than with BNT162b2. This pattern was consistent across periods marked by alpha- and delta-variant predominance. (Funded by the Department of Veterans Affairs and others.).
参考来源
- Dickerman BA, Gerlovin H, Madenci AL, et al. Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans. N Engl J Med. 2021. PMID: 34942066. doi:10.1056/NEJMoa2115463
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。